{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:44:26Z","timestamp":1790045066734,"version":"4.0.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Governments of Germany, the Netherlands and the United Kingdom"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Global Public Health"],"DOI":"10.1186\/s44263-024-00087-w","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T23:03:03Z","timestamp":1725318183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Recommendations for the optimal introduction of novel antibiotics to treat uncomplicated gonorrhoea in the face of increasing antimicrobial resistance: a case study with zoliflodacin"],"prefix":"10.1186","volume":"2","author":[{"given":"Fernando","family":"Pascual","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chido Dziva","family":"Chikwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Daram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica Espinosa","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonatan H.","family":"Grad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward WIII","family":"Hook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossaphorn","family":"Kittiyaowamarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Luckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venessa","family":"Maseko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remco P. H.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Unemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subasree","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"87_CR1","unstructured":"World Health Organization. Gonorrhoea (Neisseria gonorrhoeae infection). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/gonorrhoea-(neisseria-gonorrhoeae-infection. Accessed 25 Sept 2023."},{"key":"87_CR2","unstructured":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016\u20132021: actions for impact. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240027077. Accessed 25 Sept 2025."},{"key":"87_CR3","unstructured":"World Health Organization. Fact sheet: Multi-drug resistant gonorrhoea. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/multi-drug-resistant-gonorrhoea. Accessed 25 Sept 2023."},{"issue":"11","key":"87_CR4","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1016\/S2666-5247(21)00171-3","volume":"2","author":"M Unemo","year":"2021","unstructured":"Unemo M, Lahra MM, Escher M, Eremin S, Cole MJ, Galarza P, Ndowa F, Martin I, Dillon JR, Galas M, Ramon-Pardo P, Weinstock H, Wi T. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017\u201318: a retrospective observational study. Lancet Microbe. 2021;2(11):e627\u201336.","journal-title":"Lancet Microbe"},{"issue":"7","key":"87_CR5","doi-asserted-by":"publisher","first-page":"e1002366","DOI":"10.1371\/journal.pmed.1002366","volume":"14","author":"E Alirol","year":"2017","unstructured":"Alirol E, Wi TE, Bala M, Bazzo ML, Chen XS, Deal C, Dillon JR, Kularatne R, Heim J, Hooft van Huijsduijnen R, Hook EW, Lahra MM, Lewis DA, Ndowa F, Shafer WM, Tayler L, Workowski K, Unemo M, Balasegaram M. Multidrug-resistant gonorrhea: a research and development roadmap to discover new medicines. PLoS Med. 2017;14(7):e1002366.","journal-title":"PLoS Med."},{"issue":"Suppl 6","key":"87_CR6","doi-asserted-by":"publisher","first-page":"e25355","DOI":"10.1002\/jia2.25355","volume":"22","author":"MS Cohen","year":"2019","unstructured":"Cohen MS, Council OD, Chen JS. Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy. J Int AIDS Soc. 2019;22(Suppl 6):e25355.","journal-title":"J Int AIDS Soc"},{"key":"87_CR7","volume-title":"Antibacterial agents in clinical and preclinical development: an overview and analysis;2022","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Antibacterial agents in clinical and preclinical development: an overview and analysis;2022. 2021."},{"issue":"19","key":"87_CR8","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","volume":"379","author":"SN Taylor","year":"2018","unstructured":"Taylor SN, Marrazzo J, Batteiger BE, Hook EW 3rd, Se\u00f1a AC, Long J, Wierzbicki MR, Kwak H, Johnson SM, Lawrence K, Mueller J. Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea. N Engl J Med. 2018;379(19):1835\u201345.","journal-title":"N Engl J Med"},{"key":"87_CR9","unstructured":"Positive results announced in largest pivotal phase 3 trial of a first-in-class oral antibiotic to treat uncomplicated gonorrhoea | GARDP. Positive results in largest pivotal phase 3 trial of a novel antibiotic to treat gonorrhoea (gardp.org). https:\/\/gardp.org\/positive-results-announced-in-largest-pivotal-phase-3-trial-of-a-first-in-class-oral-antibiotic-to-treat-uncomplicated-gonorrhoea\/. Accesssed 1 Nov 2023."},{"key":"87_CR10","volume-title":"Guidelines for the management of symptomatic sexually transmitted infections","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Guidelines for the management of symptomatic sexually transmitted infections. 2021."},{"issue":"5","key":"87_CR11","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/jac\/dkab024","volume":"76","author":"M Unemo","year":"2021","unstructured":"Unemo M, Ahlstrand J, S\u00e1nchez-Bus\u00f3 L, Day M, Aanensen D, Golparian D, Jacobsson S, Cole MJ, European Collaborative Group. High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018. J Antimicrob Chemother. 2021;76(5):1221\u20138.","journal-title":"J Antimicrob Chemother."},{"issue":"13","key":"87_CR12","doi-asserted-by":"publisher","first-page":"874176","DOI":"10.3389\/fphar.2022.874176","volume":"14","author":"S Jacobsson","year":"2022","unstructured":"Jacobsson S, Golparian D, Oxelbark J, Franceschi F, Brown D, Louie A, Drusano G, Unemo M. Pharmacodynamic Evaluation of Zoliflodacin Treatment of Neisseria gonorrhoeae Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model. Front Pharmacol. 2022;14(13):874176.","journal-title":"Front Pharmacol"},{"issue":"6","key":"87_CR13","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00021","volume":"6","author":"PA Bradford","year":"2020","unstructured":"Bradford PA, Miller AA, O\u2019Donnell J, Mueller JP. Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae Including Multi-Drug-Resistant Isolates. ACS Infect Dis. 2020;6(6):1332\u201345. https:\/\/doi.org\/10.1021\/acsinfecdis.0c00021.","journal-title":"ACS Infect Dis"},{"key":"87_CR14","volume-title":"Global research agenda for antimicrobial resistance in human health. Policy Brief","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Global research agenda for antimicrobial resistance in human health. Policy Brief. 2023."},{"issue":"2","key":"87_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.idc.2023.02.003","volume":"37","author":"E Hansman","year":"2023","unstructured":"Hansman E, Klausner JD. Approach to Managing Sex Partners of People with Sexually Transmitted Infections. Infect Dis Clin North Am. 2023;37(2):405\u201326. https:\/\/doi.org\/10.1016\/j.idc.2023.02.003.","journal-title":"Infect Dis Clin North Am"},{"key":"87_CR16","volume-title":"Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. 2012."},{"key":"87_CR17","doi-asserted-by":"crossref","unstructured":"Reichert E, Yaesoubi R, R\u00f6nn MM, Gift TL, Salomon JA, Grad YH. Resistance-minimising strategies for introducing a novel antibiotic for gonorrhoea treatment: a mathematical modelling study. Lancet Microbe. 2023;4(10):e781\u20139.","DOI":"10.1016\/S2666-5247(23)00145-3"}],"container-title":["BMC Global and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44263-024-00087-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44263-024-00087-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44263-024-00087-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T23:04:30Z","timestamp":1725318270000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcglobalpublichealth.biomedcentral.com\/articles\/10.1186\/s44263-024-00087-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["87"],"URL":"https:\/\/doi.org\/10.1186\/s44263-024-00087-w","relation":{},"ISSN":["2731-913X"],"issn-type":[{"value":"2731-913X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"16 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Zoliflodacin is co-developed by the Global Antibiotic Research & Development Partnership (GARDP) in collaboration with Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA). CA, AL, PD, SS, TR and FP are employees of GARDP. GARDP covered the expenses for RK. CD, HE, RK and MU have participated in zoliflodacin development. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}